Novel compounds and pharmaceutical compositions useful as EGFR tyrosine kinase inhibitors. Methods of the invention include administration of the EGFR TK inhibitors to treat diseases characterized by enhanced expression of EGF, including cancers, particularly breast cancer. Additionally, a homology model representing the structure of EGFR kinase domain is provided, which model is useful for the rationally design and screening of compounds predicted to bind favorably to EGFR and to inhibit EGFR TK.
小说化合物和药物组合物可用作
EGFR
酪氨酸激酶
抑制剂。本发明的方法包括给予
EGFR TK
抑制剂治疗由
EGF过度表达所特征的疾病,包括癌症,特别是乳腺癌。此外,提供了代表
EGFR激酶结构域结构的同源模型,该模型可用于有理设计和筛选预测有利于与
EGFR结合并抑制
EGFR TK的化合物。